Back to Oncology
Oncologyv2019Evidence-Based

Graded Prognostic Assessment for Gastrointestinal Cancer (GI-GPA)

Estimates survival in patients with gastrointestinal cancers and brain metastases. Uses 4 prognostic factors to provide risk stratification and guide treatment decisions for patients with brain metastases from GI cancers.

Clinical Input Parameters

years
Clinical Assessment
Awaiting Parameters
gi gpa score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Graded Prognostic Assessment for Gastrointestinal Cancer (GI-GPA) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

GI-GPA Score = Age points (0-0.5) + KPS points (0-2) + Extracranial metastases points (0-0.5) + Number of brain metastases points (0-1)

Clinical Pearls & Practice Notes

  • Developed from multi-institutional cohort of 845 patients with GI cancers and newly diagnosed brain metastases
  • Applicable to various gastrointestinal cancer types including colorectal, gastric, esophageal, and hepatobiliary cancers
  • Score ranges from 0.0 (worst prognosis) to 4.0 (best prognosis)
  • Should be used in conjunction with clinical judgment and patient preferences
  • Helps guide treatment selection and end-of-life decision-making
  • Useful for stratification in clinical trials involving brain metastases
  • Free online calculator available at brainmetgpa.com
  • Consider multidisciplinary team approach for treatment planning

Evidence & Literature Citations

  1. Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, et al. Estimating survival in patients with gastrointestinal cancers and brain metastases: An update of the graded prognostic assessment for gastrointestinal cancers (GI-GPA). Clin Transl Radiat Oncol. 2019;18:39-45. doi: 10.1016/j.ctro.2019.06.009.
  2. Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010;77(3):655-61. doi: 10.1016/j.ijrobp.2009.08.025.
  3. Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, et al. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). JAMA Oncol. 2017;3(6):827-831. doi: 10.1001/jamaoncol.2016.3834.

Score Interpretation Ranges

Poor Prognosis0 – 1 pts

Worst survival group

Intermediate-Poor Prognosis1.5 – 2 pts

Below average survival

Intermediate Prognosis2.5 – 3 pts

Average survival

Good Prognosis3.5 – 4 pts

Best survival group

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.